260 related articles for article (PubMed ID: 26951085)
1. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI.
Kim E; Kim J; Maelandsmo GM; Johansen B; Moestue SA
Magn Reson Med; 2017 Oct; 78(4):1513-1522. PubMed ID: 27888545
[TBL] [Abstract][Full Text] [Related]
3. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS
NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
Jing Y; Xiu-Juan Z; Hong-Jiao C; Zhi-Kui C; Qing-Fu Q; En-Sheng X; Li-Wu L
J Cancer Res Clin Oncol; 2019 May; 145(5):1191-1200. PubMed ID: 30805775
[TBL] [Abstract][Full Text] [Related]
5. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
6. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
Moestue SA; Dam CG; Gorad SS; Kristian A; Bofin A; Mælandsmo GM; Engebråten O; Gribbestad IS; Bjørkøy G
Breast Cancer Res; 2013 Feb; 15(1):R16. PubMed ID: 23448424
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
8. Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells.
Tunset HM; Feuerherm AJ; Selvik LM; Johansen B; Moestue SA
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569627
[TBL] [Abstract][Full Text] [Related]
9. Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.
Esmaeili M; Bathen TF; Engebråten O; Mælandsmo GM; Gribbestad IS; Moestue SA
Magn Reson Med; 2014 Jun; 71(6):1973-81. PubMed ID: 23878023
[TBL] [Abstract][Full Text] [Related]
10. Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases.
Li Z; Qu M; Sun Y; Wan H; Chai F; Liu L; Zhang P
Biochem Biophys Res Commun; 2018 Jan; 496(1):153-158. PubMed ID: 29307829
[TBL] [Abstract][Full Text] [Related]
11. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
12. Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer.
Kung PP; Martinez R; Zhu Z; Zager M; Blasina A; Rymer I; Hallin J; Xu M; Carroll C; Chionis J; Wells P; Kozminski K; Fan J; Guicherit O; Huang B; Cui M; Liu C; Huang Z; Sistla A; Yang J; Murray BW
Mol Cancer Ther; 2014 Aug; 13(8):2104-15. PubMed ID: 24928852
[TBL] [Abstract][Full Text] [Related]
13. Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer.
Flister MJ; Tsaih SW; Stoddard A; Plasterer C; Jagtap J; Parchur AK; Sharma G; Prisco AR; Lemke A; Murphy D; Al-Gizawiy M; Straza M; Ran S; Geurts AM; Dwinell MR; Greene AS; Bergom C; LaViolette PS; Joshi A
Breast Cancer Res Treat; 2017 Aug; 165(1):53-64. PubMed ID: 28567545
[TBL] [Abstract][Full Text] [Related]
14. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
Chen X; Meng Q; Zhao Y; Liu M; Li D; Yang Y; Sun L; Sui G; Cai L; Dong X
Cancer Lett; 2013 Jan; 328(2):318-24. PubMed ID: 23092556
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
Huynh H; Ong R; Zopf D
J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
[TBL] [Abstract][Full Text] [Related]
18. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
Sorace AG; Quarles CC; Whisenant JG; Hanker AB; McIntyre JO; Sanchez VM; Yankeelov TE
Breast Cancer Res Treat; 2016 Jan; 155(2):273-84. PubMed ID: 26791520
[TBL] [Abstract][Full Text] [Related]
20. Abrus agglutinin is a potent anti-proliferative and anti-angiogenic agent in human breast cancer.
Bhutia SK; Behera B; Nandini Das D; Mukhopadhyay S; Sinha N; Panda PK; Naik PP; Patra SK; Mandal M; Sarkar S; Menezes ME; Talukdar S; Maiti TK; Das SK; Sarkar D; Fisher PB
Int J Cancer; 2016 Jul; 139(2):457-66. PubMed ID: 26914517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
